ImmunoCellular to Present at the 14th Annual BIO CEO & Investor Conference: ImmunoCellular Therapeutics, Ltd. (?ImmunoCellular? or the ?Company?) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that its president and CEO, Manish Singh Ph.D., will be presenting at the upcoming 14th annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh?s presentation will take place on Monday, February 13th, 2012 at 1:00 pm. The presentation will be webcast following registration at the web address below: http://www.veracast.com/webcasts/bio/ceoinvestor2012/06110111.cfm.
Vergrößern ImmunoCellular to Present at the 14th Annual BIO CEO & Investor Conference | Bild: © ad-hoc-news

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens including those associated with cancer stem cells for glioblastoma treatment. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that any patents issued covering IMUC?s vaccine technology will not provide significant commercial protection for IMUC?s technology or products; the risk that the safety and efficacy results obtained in the Phase IMUC trial for the dendritic cell- based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.